What’s Ahead for Biosimilars


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

Product Description

Biosimilars could represent a multi-billion dollar market in the United States, although some questions remain, including the uptake by physicians and payers, pricing of biosimilars, and how the Food and Drug Administration will review such products.
Alan Sheppard, global head of generics at IMS Health, says many biopharmaceuticals are premium priced and because of this, usage is either restricted by payers or unaffordable for…

David Fox
. Partner, Life Science Practice, Hogan Lovells, a global legal practice. For more information, visit
Jeff George. Division Head, Sandoz, the generic pharmaceuticals division of Novartis. For more information, visit
Peyton Howell. President of AmerisourceBergen Consulting Services and Senior VP of Business Development for Amerisource-Bergen, which provides drug distribution and related services designed to reduce costs and improve patient outcomes. For more information, visit
Alan Sheppard. Global Head, Generics, IMS Health, a provider of information services for the healthcare industry. For more
information, visit